Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has reported that patients with ankylosing spondylitis who received its Remicade drug over two years experienced significant improvement in spinal mobility.
Subscribe to our email newsletter
According to data presented at the Annual European Congress of Rheumatology, Remicade (infliximab)-treated patients showed sustained reductions in spinal inflammation through two years as detected by magnetic resonance imaging (MRI).
In the trial, 201 patients treated with infliximab scored higher on tests of mobility and quality of life than 78 patients given a placebo. Additionally, the improvement observed after six months was maintained through week 102.
“These data demonstrate that treatment with Remicade improved spinal mobility. Over time, this improvement can be maintained when Remicade is coupled with physiotherapy,” said Jurgen Braun, professor of rheumatology at the Free University of Berlin.